Literature DB >> 22703678

Breast-feeding success among infants with phenylketonuria.

Sandra A Banta-Wright1, Kathleen C Shelton, Nancy D Lowe, Kathleen A Knafl, Gail M Houck.   

Abstract

Breast milk is the nutrition of choice for human infants (American Academy of Pediatrics, 2005; American Association of Family Physicians, 2008; Association of Women's Health Obstetric and Neonatal Nurses, 2005; Canadian Paediatric Society, 2005; U.S. Preventive Services Task Force, 2008; World Health Organization, 2009). In comparison to standard commercial formula, human breast milk has a lower concentration of protein and a lower content of the amino acid phenylalanine (Phe). For infants with phenylketonuria (PKU), these attributes of human breast milk make it ideal as a base source of nutrition. The purpose of this study was to compare the incidence and duration of breast-feeding and corresponding Phe levels of breast-fed and formula-fed infants with PKU in the caseload of a pediatric metabolic clinic at an urban tertiary-care medical center. Charts were reviewed for infants diagnosed with PKU beginning with 2005 and ending with 1980, the year no further breast-feeding cases were identified in the PKU population. During the first year of life, most of the infants, whether breast-fed or formula-fed, had similar mean Phe levels. However, the frequency distributions revealed that more breast-fed infants with PKU had Phe levels within the normal range (120-360 μmol/L) and were less likely to have low Phe levels (<120 μmol/L) than formula-fed infants with PKU. Further research is needed to understand how mothers manage breast-feeding in the context of PKU.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22703678      PMCID: PMC3383634          DOI: 10.1016/j.pedn.2011.03.015

Source DB:  PubMed          Journal:  J Pediatr Nurs        ISSN: 0882-5963            Impact factor:   2.145


  26 in total

1.  Phenylpyruvic oligophrenia deficiency of phenylalanine-oxidizing system.

Authors:  G A JERVIS
Journal:  Proc Soc Exp Biol Med       Date:  1953-03

2.  Neonatal screening: from the 'Guthrie age' to the 'genetic age'.

Authors:  Jean-Louis Dhondt
Journal:  J Inherit Metab Dis       Date:  2007-05-12       Impact factor: 4.982

3.  Exclusive breastfeeding should continue to six months.

Authors:  Margaret Boland
Journal:  Paediatr Child Health       Date:  2005-03       Impact factor: 2.253

4.  Breastfeeding in phenylketonuria.

Authors:  K Motzfeldt; R Lilje; G Nylander
Journal:  Acta Paediatr Suppl       Date:  1999-12

5.  Breastfeeding and the use of human milk.

Authors:  Lawrence M Gartner; Jane Morton; Ruth A Lawrence; Audrey J Naylor; Donna O'Hare; Richard J Schanler; Arthur I Eidelman
Journal:  Pediatrics       Date:  2005-02       Impact factor: 7.124

Review 6.  Breastfeeding and maternal and infant health outcomes in developed countries.

Authors:  Stanley Ip; Mei Chung; Gowri Raman; Priscilla Chew; Nombulelo Magula; Deirdre DeVine; Thomas Trikalinos; Joseph Lau
Journal:  Evid Rep Technol Assess (Full Rep)       Date:  2007-04

Review 7.  Variables associated with breastfeeding duration.

Authors:  Diane Thulier; Judith Mercer
Journal:  J Obstet Gynecol Neonatal Nurs       Date:  2009 May-Jun

8.  Indices of protein metabolism in term infants fed human milk, whey-predominant formula, or cow's milk formula.

Authors:  L M Janas; M F Picciano; T F Hatch
Journal:  Pediatrics       Date:  1985-04       Impact factor: 7.124

9.  [Phenylketonuria diagnosed during the neonatal period and breast feeding].

Authors:  Verónica Cornejo; Viviana Manríquez; Marta Colombo; Paulina Mabe; Mónica Jiménez; Alicia De la Parra; Alf Valiente; Erna Raimann
Journal:  Rev Med Chil       Date:  2003-11       Impact factor: 0.553

10.  Factors associated with breastfeeding at six months postpartum in a group of Australian women.

Authors:  Della A Forster; Helen L McLachlan; Judith Lumley
Journal:  Int Breastfeed J       Date:  2006-10-12       Impact factor: 3.461

View more
  6 in total

Review 1.  Antioxidant treatment strategies for hyperphenylalaninemia.

Authors:  Priscila Nicolao Mazzola; George Albert Karikas; Kleopatra H Schulpis; Carlos Severo Dutra-Filho
Journal:  Metab Brain Dis       Date:  2013-05-09       Impact factor: 3.584

2.  Breastfeeding infants with phenylketonuria in the United States and Canada.

Authors:  Sandra A Banta-Wright; Nancy Press; Kathleen A Knafl; Robert D Steiner; Gail M Houck
Journal:  Breastfeed Med       Date:  2013-12-18       Impact factor: 1.817

Review 3.  The complete European guidelines on phenylketonuria: diagnosis and treatment.

Authors:  A M J van Wegberg; A MacDonald; K Ahring; A Bélanger-Quintana; N Blau; A M Bosch; A Burlina; J Campistol; F Feillet; M Giżewska; S C Huijbregts; S Kearney; V Leuzzi; F Maillot; A C Muntau; M van Rijn; F Trefz; J H Walter; F J van Spronsen
Journal:  Orphanet J Rare Dis       Date:  2017-10-12       Impact factor: 4.123

4.  Breastfeeding in Phenylketonuria: Changing Modalities, Changing Perspectives.

Authors:  Juri Zuvadelli; Sabrina Paci; Elisabetta Salvatici; Federica Giorgetti; Graziella Cefalo; Alice Re Dionigi; Valentina Rovelli; Giuseppe Banderali
Journal:  Nutrients       Date:  2022-10-05       Impact factor: 6.706

5.  Nuclear Magnetic Resonance Metabolomics Reveals Qualitative and Quantitative Differences in the Composition of Human Breast Milk and Milk Formulas.

Authors:  Dorota Garwolińska; Weronika Hewelt-Belka; Agata Kot-Wasik; Ulrik Kræmer Sundekilde
Journal:  Nutrients       Date:  2020-03-27       Impact factor: 5.717

6.  Early feeding practices in infants with phenylketonuria across Europe.

Authors:  A Pinto; S Adams; K Ahring; H Allen; M F Almeida; D Garcia-Arenas; N Arslan; M Assoun; Y Atik Altınok; D Barrio-Carreras; A Belanger Quintana; S M Bernabei; C Bontemps; F Boyle; G Bruni; M Bueno-Delgado; G Caine; R Carvalho; A Chrobot; K Chyż; B Cochrane; C Correia; K Corthouts; A Daly; S De Leo; A Desloovere; A De Meyer; A De Theux; B Didycz; M E Dijsselhof; K Dokoupil; J Drabik; C Dunlop; W Eberle-Pelloth; K Eftring; J Ekengren; I Errekalde; S Evans; A Foucart; L Fokkema; L François; M French; E Forssell; C Gingell; C Gonçalves; H Gökmen Özel; A Grimsley; G Gugelmo; E Gyüre; C Heller; R Hensler; I Jardim; C Joost; M Jörg-Streller; C Jouault; A Jung; M Kanthe; N Koç; I L Kok; T Kozanoğlu; B Kumru; F Lang; K Lang; I Liegeois; A Liguori; R Lilje; O Ļubina; P Manta-Vogli; D Mayr; C Meneses; C Newby; U Meyer; S Mexia; C Nicol; U Och; S M Olivas; C Pedrón-Giner; R Pereira; K Plutowska-Hoffmann; J Purves; A Re Dionigi; K Reinson; M Robert; L Robertson; J C Rocha; C Rohde; S Rosenbaum-Fabian; A Rossi; M Ruiz; J Saligova; A Gutiérrez-Sánchez; A Schlune; K Schulpis; J Serrano-Nieto; A Skarpalezou; R Skeath; A Slabbert; K Straczek; M Giżewska; A Terry; R Thom; A Tooke; J Tuokkola; E van Dam; T A M van den Hurk; E M C van der Ploeg; K Vande Kerckhove; M Van Driessche; A M J van Wegberg; K van Wyk; C Vasconcelos; V Velez García; J Wildgoose; T Winkler; J Żółkowska; J Zuvadelli; A MacDonald
Journal:  Mol Genet Metab Rep       Date:  2018-08-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.